In this issue:
Cytogenetic abnormalities in Philadelphia-negative ALL
Cladribine with concurrent or delayed rituximab in hairy cell leukaemia
Survival in second primary Hodgkin lymphoma
Multiagent vs single-agent chemo in older adults with AML
CPX-351 in high risk or secondary AML
Impaired immune health in DLBCL survivors
Primary dural lymphomas
Time from diagnosis to treatment in AML
Vincristine dose cap and neuropathies with DA-EPOCH-R
Dasatinib ± PPIs and H2RAs in CML
Please login below to download this issue (PDF)